Abstract
Giant cell arteritis (GCA) is a chronic granulomatous vasculitis of unknown aetiology occurring in the elderly. It affects the cranial branches of the arteries originating from the aortic arch and is usually associated with markedly elevated acute-phase reactants. In 10–15% of cases the extra-cranial branches of the aortic arch are involved. GCA is closely related to polymyalgia rheumatica (PMR), although the relationship between the two disorders is still unclear. New-onset headache, scalp tenderness, jaw claudication, temporal artery abnormalities on physical examination, visual symptoms and associated PMR represent the most typical and frequent features of the disease. Systemic manifestations, including fever, anorexia and weight loss, are observed in 50% of cases. Less frequent manifestations are related to the central or peripheral nervous systems, the respiratory tract and extra-cranial large-vessel involvement. As GCA is characterized by a wide spectrum of clinical manifestations, it is important to recognize the different onset patterns of the disease and related diagnostic steps. The diagnosis is relatively straightforward in the presence of typical cranial manifestations, but it may be challenging in the case of a normal erythrocyte sedimentation rate, occult GCA or in patients with isolated extra-cranial features. Temporal artery biopsy still represents the gold standard for diagnosis, while the role of ultrasonography, high-resolution magnetic resonance imaging and positron emission tomography should be better addressed. Corticosteroids remain the therapy of choice. Data supporting the usefulness of antiplatelet agents and anticoagulants combined with corticosteroids to prevent ischaemic complications as well as the corticosteroidsparing effect of methotrexate and anti-tumour necrosis factor-α drugs are limited and non-conclusive.
Similar content being viewed by others
References
Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant cell arteritis. N Engl J Med 2002 Jul 25; 347(4): 261–71
Portioli I. The history of polymyalgia rheumatica/giant cell arteritis. Clin Exp Rheumatol 2000 Jul–Aug; 18 (4 Suppl. 20): S1–3
Hutchinson J. Diseases of the arteries: on a peculiar form of thrombotic arteritis of the aged which is sometimes productive of gangrene. Arch Surg 1890; 1: 323–9
Horton BT, Magath TB, Brown GE. An undescribed form of arteritis of the temporal vessels. Mayo Clin Proc 1932; 7: 700–1
Gilmore JR. Giant cell arteritis. J Pathol Bacteriol 1941; 53: 263–77
Lie JT. Illustrated histopathologic classification criteria for selected vasculitis syndromes. Arthritis Rheum 1990 Aug; 33(8): 1074–87
Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990–2001. Ann Rheum Dis 2006; 65: 1093–8
Salvarani C, Gabriel SE, O’Fallon WM, et al. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 1995; 123: 192–4
Doran MF, Crowson CS, O’Fallon WM, et al. Trends in the incidence of PMR over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol 2002; 29: 1694–7
Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, et al. Giant cell arteritis in northwestern Spain: a Gonzalez 25-year epidemiologic study. Medicine (Baltimore) 2007 Mar; 86(2): 61–8
Salvarani C, Macchioni P, Zizzi F, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991; 34: 351–6
Kobayashi S, Yano T, Matsumoto Y, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum 2003 Aug 15; 49(4): 594–8
Gonzalez EB, Varner WT, Lisse JR, et al. Giant-cell arteritis in the southern United States: an 11-year retrospective study from the Texas Gulf Coast. Arch Intern Med 1989 Jul; 149(7): 1561–5
Lam BL, Wirthlin RS, Gonzalez A, et al. Giant cell arteritis among Hispanic Americans. Am J Ophthalmol 2007 Jan; 143(1): 161–3
Paulley JW, Hughes JP. Giant cell arteritis, or arteritis of the aged. BMJ 1960; 2: 1562–7
Wilske KR, Healey LA. Polymyalgia rheumatica: a manifestation of systemic giant cell arteritis. Ann Intern Med 1965; 66: 77–91
Boesen P, Sorenson SF. Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica. Arthritis Rheum 1987 Mar; 30(3): 294–9
Bengtsson BA, Malmvall BE. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Arthritis Rheum 1981 Jul; 24(7): 899–904
Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum 2004 Apr; 33(5): 289–93
Cantini F, Niccoli L, Storri L, et al. Are polymyalgia rheumatica and giant cell arteritis the same disease? Semin Arthritis Rheum 2004 Apr; 33(5): 294–301
Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C, et al. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 2003 Aug; 33(1): 38–48
Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 1996 Jan; 23(1): 112–9
Helling H, Olsson AT, Elling P. Human parvovirus and giant cell arteritis: a selective arteritic impact? Clin Exp Rheumatol 2000; 18 (4 Suppl. 20): S12–4
Cimmino M, Grazi MA, Balistreri M, et al. Increased prevalence of antibodies to adenovirus and respiratory syncytial virus in polymyalgia rheumatica. Clin Exp Rheumatol 1993 May–Jun; 11(3): 309–13
Wagner A, Gerard HC, Fresemann T, et al. Detection of Chlamydia pneumoniae in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells. Arthritis Rheum 2000 Jul; 43(7): 1543–51
Gabriel SE, Espy M, Erdman DD, et al. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: a preliminary evaluation. Arthritis Rheum 1999 Jun; 42(6): 1255–8
Salvarani C, Farnetti E, Casali B, et al. Detection of parvovirus B19 DNA by polymerase chain reaction in giant cell arteritis: a case-control study. Arthritis Rheum 2002 Nov; 46(11): 3099–101
Regan MJ, Wood BJ, Hsieh YH, et al. Temporal arteritis and Chlamydia pneumoniae: failure to detect the organism by polymerase chain reaction in ninety cases and ninety controls. Arthritis Rheum 2002 Apr; 46(4): 1056–60
Helveg-Larsen J, Tarp B, Obel N, et al. No evidence of parvovirus B19, Chlamydia pneumoniae or human herpes virus infection in temporal artery biopsies in patients with giant cell arteritis. Rheumatology (Oxford) 2002 Apr; 41(4): 445–9
Duhaut P, Bosshard S, Calvet A, et al. Giant cell arteritis, polymyalgia rheumatica and viral hypotheses: a multicentric, prospective case-control study. J Rheumatol 1999 Feb; 26(2): 361–9
Narvaez J, Clavaguera MT, Nolla-Solé JM, et al. Lack of association between infection and onset of PMR. J Rheumatol 2000 Apr; 27(4): 953–7
Weyand CM, Goronzy JJ. Arterial wall injury in giant cell arteritis. Arthritis Rheum 1999 May; 42(5): 844–53
Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003 Sep; 139(6): 505–15
Calamia KT, Hunder GG. Clinical manifestations of giant cell (temporal) arteritis. Clin Rheum Dis 1980; 6: 389–403
Calamia KT, Hunder GG. Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin. Arthritis Rheum 1981 Nov; 24(11): 1414–8
Huston KA, Hunder GG, Lie JT, et al. Temporal arteritis: a 25-year epidemiologic, clinical and pathologic study. Ann Intern Med 1978 Feb; 88(2): 162–7
Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA 2002 Jan; 287(1): 92–101
Soderstrom CW, Seehafer JR. Bilateral scalp necrosis in temporal arteritis. Am J Med 1976 Oct; 61(4): 541–6
Currey J. Case report: scalp necrosis in giant cell arteritis and review of the literature. Br J Rheumatol 1997 Jul; 36(7): 814–6
Nir-Paz R, Gross A, Chajek-Shaul T. Reduction of jaw opening (trismus) in giant cell arteritis. Ann Rheum Dis 2002 Mar; 61(3): 832–3
Aiello PD, Trautmann JC, McPhee TJ, et al. Visual prognosis in giant cell arteritis. Ophthalmology 1993 Apr; 100(4): 550–6
Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998 Aug; 41(8): 1497–504
Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998 Apr; 125(4): 742–4
Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al. Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients. Medicine (Baltimore) 2000 Sep; 79(5): 283–92
Nesher G, Nesher R, Rozenman Y, et al. Visual hallucinations in giant cell arteritis: association with visual loss. J Rheumatol 2001 Apr; 28(4): 2046–8
Caselli R, Hunder GG, Whisnant JP. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology 1988 Mar; 38(3): 352–9
Caselli R, Daube JR, Hunder GG, et al. Peripheral neuropathic syndromes in giant cell (temporal) arteritis. Neurology 1988 May; 38(5): 685–9
Larson TS, Hall S, Hepper NG, et al. Respiratory tract symptoms as a clue to giant cell arteritis. Ann Intern Med 1984 Nov; 101(5): 594–7
Klein RG, Hunder GG, Stanson AW, et al. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 1975 Dec; 83(6): 806–12
Brack A, Martinez-Taboada V, Stanson A, et al. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 1999 Feb; 42(2): 311–7
Bongartz T, Matteson E. Large-vessel involvement in giant cell arteritis. Curr Opin Rheumatol 2006 Jan; 18(1): 10–7
Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. Ann Intern Med 1995 Apr; 122(7): 502–7
Gonzalez-Gay MA, Garcia-Porrua C, Pineiro A, et al. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore) 2004 Nov; 83(6): 335–41
Nuenninghoff DM, Hunder GG, Christianson TJH, et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis. Arthritis Rheum 2003 Dec; 48(12): 3522–31
Salvarani C, Macchioni L, Boiardi L. Polymyalgia rheumatica. Lancet 1997 Jul; 350(9070): 43–7
Chuang T-Y, Hunder GG, Ilstrup DM, et al. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982 Nov; 97(5): 672–80
Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984 May; 13(4): 322–8
Salvarani C, Cantini F, Olivieri I, et al. Polymyalgia rheumatica: a disorder of extraarticular synovial structures? J Rheumatol 1999 Mar; 26(3): 517–21
Salvarani C, Cantini F, Macchioni L, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective follow-up study. Arthritis Rheum 1998 Jul; 41(7): 1221–6
Blockmans D, de Ceuninck L, Vanderschueren S, et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 2006 Feb; 55(1): 131–7
Salvarani C, Cantini F, Olivieri I, et al. Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med 1997 Jul; 127(1): 27–31
Cantini F, Salvarani C, Olivieri I, et al. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. J Rheumatol 2001 May; 28(5): 1049–55
Cantini F, Salvarani C, Olivieri I, et al. Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate. Arthritis Rheum 2001 May; 44(5): 1155–9
Cantini F, Niccoli L, Nannini C, et al. Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin Exp Rheumatol 2005 Jul–Aug; 23(4): 462–8
Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population-based study. Arthritis Rheum 2001 Apr; 45(2): 140–5
Salvarani C, Cimino L, Macchioni P, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 2005 Apr; 53(2): 293–7
Salvarani C, Gabriel SE, O’Fallon WM, et al. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970–1991. Arthritis Rheum 1995 Mar; 38(3): 369–73
Franzén P, Sutinen S, Von Knorring J. Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984–1988. J Rheumatol 1992 Feb; 19(2): 273–80
Salvarani C, Silingardi M, Ghirarduzzi A, et al. Is duplex ultrasonography useful for the diagnosis of giant cell arteritis? Ann Intern Med 2002 Aug; 137(4): 232–8
Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S, et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Baltimore) 2005 Sep; 84(5): 277–90
Schmidt WA, Kraft HE, Vorpahl K, et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997; 337: 1336–42
Gonzalez-Gay MA, Garcia-Porrua C, Amor-Dorado JC, et al. Fever in biopsy-proven giant cell arteritis: clinical implications in a defined population. Arthritis Rheum 2004 Aug 15; 51(4): 652–5
Woolery WA, Franco FR. Fever of unknown origin: keys to determining the etiology in older patients. Geriatrics 2004 Oct; 59(10): 41–5
Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol 1998 Apr; 125(4): 521–6
Weiss LB, Gonzalez E, Miller SB, et al. Severe anemia as the presenting manifestation of giant cell arteritis. Arthritis Rheum 1995 Mar; 38(3): 434–6
Bablekos GD, Michaelidis SA, Karachalios GN, et al. Pericardial involvement as an atypical manifestation of giant cell arteritis: report of a clinical case and literature review. Am J Med Sci 2006 Oct; 332(4): 198–204
Gur H, Ehrenfeld M, Izsak E. Pleural effusion as a presenting manifestation of giant cell arteritis. Clin Rheumatol 1996 Mar; 15(2): 200–3
Karagiannis A, Mathiopoulou L, Tziomalos K, et al. Dry cough as first manifestations of giant cell arteritis. J Am Geriatr Soc 2006 Dec; 54(12): 1957–8
Lazaridis C, Torabi A, Cannon S. Bilateral third nerve palsy and temporal arteritis. Arch Neurol 2005 Nov; 62(11): 1766–8
Nesher G, Rosenberg P, Shorer Z, et al. Involvement of the peripheral nervous system in temporal arteritis-polymyalgia rheumatica: report of 3 cases and review of the literature. J Rheumatol 1987 Apr; 14(2): 358–60
Patel RK, Carrick K. Giant cell arteritis of the female genital tract: report of a case and review of the literature. South Med J 2005 Apr; 98(4): 469–71
Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell (temporal) arteritis. Arthritis Rheum 1990 Aug; 33(8): 1122–8
Weyand CM, Fullbright JW, Hunder GG, et al. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000 May; 43(5): 1041–8
Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective, follow-up study. Semin Arthritis Rheum 2000 Aug; 30(1): 17–24
Parikh M, Miller NR, Lee AG, et al. Prevalence of normal C-reactive protein with elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology 2006 Oct; 113(10): 1842–5
Esteban M-J, Font C, Hernandez-Rodriguez J, et al. Small-vessel vasculitis surrounding a spared temporal artery: clinical and pathologic findings in a series of twenty-eight patients. Arthritis Rheum 2001 Jun; 44(6): 1387–95
Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med 1998 Sep; 129(5): 345–52
Gonzalez-Gay MA. The diagnosis and management of patients with giant cell arteritis. J Rheumatol 2005 Jul; 32(7): 1186–8
Achkar AA, Lie JT, Hunder GG, et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994 Jun; 120(12): 987–92
Karahaliou M, Vaiopoulos G, Papaspyrou S, et al. Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis. Arthritis Res Ther 2006 Jul; 8(4): R116
Bley TA, Wieben O, Uhl M, et al. High-resolution MRI in giant cell arteritis: imaging of the wall of the superficial temporal artery. AJR Am J Roentgenol 2005 Jan; 184(1): 283–7
Markl M, Uhl M, Wieben O, et al. High-resolution 3T MRI for the assessment of cervical and superficial cranial arteries in giant cell arteritis. J Magn Reson Imaging 2006 Aug; 24(2): 423–7
Chavaillaz O, Gueddi S, Taylor S, et al. Giant cell arteritis mimicking fever of unknown origin: potential diagnostic role of PET scan. Thromb Haemost 2006 Feb; 95(2): 390–2
Salvarani C, Gabriel SE, Gertz MA, et al. Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 1994 Nov; 37(11): 1621–6
Machado EB, Michet CJ, Ballard DJ, et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950–1985. Arthritis Rheum 1988 Jun; 31(6): 745–9
Hunder GG, Sheps SG, Allen GL, et al. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med 1975 May; 82(5): 613–8
Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006 Sep; 54(10): 3310–8
Andersson R, Malmvall B-E, Bengtsson B-A. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 1986; 220(5): 465–9
Gabriel SE, Sunku J, Salvarani C, et al. Adverse outcomes of anti-inflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997 Oct; 40(10): 1873–8
Nesher G, Sonnenblick M, Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994 Jul; 21(7): 1283–6
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001 Jul; 44(7): 1496–503
Lee MS, Smith SD, Galor A, et al. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006 Oct; 54(10): 3306–9
Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004 Apr; 50(4): 1332–7
Gonzalez-Gay MA, Pineiro A, Gomez-Gigirey A, et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore) 2004 Nov; 83(6): 342–7
Narvaez J, Bernad B, Nolla JM, et al. Statin therapy does not seem to benefit giant cell arteritis. Semin Arthritis Rheum 2007; 36(5): 322–7
Both M, Aries PM, Muller-Hulsbeck S, et al. Balloon angioplasty of arteries of the upper extremities in patients with extracranial giant cell arteritis. Ann Rheum Dis 2006 Sept; 65(9): 1124–30
Jover JA, Hernandez-Garcia C, Morado IC, et al. Combined treatment of giant cell arteritis with methotrexate and prednisone. Ann Intern Med 2001 Jan; 134(2): 106–14
Hoffman GS, Hellmann DB, Guillevin L, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002 May; 46(5): 1309–18
Weyand CM, Hicock KC, Hunder GG, et al. Tissue cytokine patterns in polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994 Oct; 121(7): 484–91
Field M, Cook A, Gallagher G. Immuno-localisation of tumor necrosis factor and its receptors in temporal arteritis. Rheumatol Int 1997; 17(3): 113–8
Cantini F, Niccoli L, Salvarani C, et al. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001 Dec; 44(12): 2933–5
Airo P, Antonioli CM, Vianelli M, et al. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 2002 Mar; 41(3): 347–9
Uthman I, Kanj N, Atweh S. Infliximab as monotherapy in giant cell arteritis. Clin Rheumatol 2006 Feb; 25(1): 109–10
Tan AL, Holdsworth J, Pease C, et al. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003 Apr; 62(4): 373–4
Ahmed MM, Mubashir E, Hayat S, et al. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol 2007 Aug; 26(8): 1353–5
Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007 May 1; 146(9): 621–30
Acknowledgements
No sources of funding were used to assist in the preparation of this article. The authors have no conflicts of interest that are directly relevant to the content of this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cantini, F., Niccoli, L., Nannini, C. et al. Diagnosis and Treatment of Giant Cell Arteritis. Drugs Aging 25, 281–297 (2008). https://doi.org/10.2165/00002512-200825040-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-200825040-00002